AmInvestment said Mah Sing’s financial year (FY) 2021’s new sales amounting to RM1.6bil (up 45% y-o-y) came in within expectations.aws试用账号（www.2km.me）提供aws账号、aws全区号、aws32v账号、亚马逊云账号出售，提供api ，质量稳定，数量持续。另有售azure oracle linode等账号.
PETALING JAYA: Mah Sing Group Bhd’s sales will be supported by the property developer’s plans to launch projects worth RM2.4bil this year, a 71% increase year-on-year (y-o-y).
The group has 21 projects in the pipeline with upcoming launches focused mainly on the Klang Valley even as it planned new developments in Perak, Negri Sembilan and Melaka.
The launches include M Senyum in Sepang, M Astra in Setapak and M Nova in Kepong.
AmInvestment Bank Research, in a report, noted that 60% of the products will be priced below RM500,000 while 34% are to be priced at between RM500,000 and RM700,000.
The company managed to launch products worth RM1.4bil last year.
AmInvestment said Mah Sing’s financial year (FY) 2021’s new sales amounting to RM1.6bil (up 45% y-o-y) came in within expectations.
This was underpinned by the group’s strong execution model and residential projects targeted at strategic locations together with savvy pricing schemes according to market demand.
Additionally, none of the developments were affected by the recent floods in the country.
It added that the strong sales mainly stemmed from the affordable M Series developments located in the Klang Valley.
Note that high-rise products including M Centura in Sentul, M Vertica in Cheras and landed properties M Aruna in Rawang have received a take-up rate of more than 90%.
“The attractive pricing strategy has gained substantial interest from first-time home buyers who are below 35 years old (66%),” the research house said.
On its glove manufacturing business, it said a total of 12 lines are fully operational with a maximum production capacity of 3.7 billion pieces of gloves per year.
The company recently received the FDA 510K, Health Canada Medical Device Licence and Certificate of European Union (EU) Medical Device Regulation for medical gloves to be exported to the United States, Canada, the EU and EEA territories.
It remained positive on the company’s property sales trajectory and glove manufacturing capacity expansion given the group’s quick turnaround business model and higher selling price of medical gloves to key markets. It maintained its “buy’’ call on the stock with an unchanged fair value of 95 sen per share.